Completed PHASE3 INTERVENTIONAL 4-arm NCT01172821

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II

A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 µg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 µg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma

Sponsor: Boehringer Ingelheim

Conditions Asthma

Interventions 50 mcg salmeterol HFA MDI placebo tiotropium Respimat® high dose tiotropium Respimat® low dose

Updated 2 times since 2024 Last updated: Jun 3, 2014 Started: Aug 31, 2010 Primary completion: Nov 30, 2012 Completion: Nov 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Asthma, this trial is completed. The trial is conducted by Boehringer Ingelheim and has accumulated 2 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

2 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3

First recorded

Aug 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boehringer Ingelheim
Pfizer

Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ahmedabad, India , Aira, Kagoshima, Japan , Bamberg, Germany , Berlin, Germany , Bialystok, Poland , Bogotá, Colombia , Bozeman, United States , Brasov, Romania , Bucharest, Romania , Bydgoszcz, Poland and 87 more locations